SOLX, a privately held, Waltham-based developer of surgical treatments for glaucoma, has raised $3.3 million in a venture capital deal, the company disclosed in a new filing with the Securities and Exchange Commission. Three separate investors participated in the offering.

SOLX, Inc. is an emerging leader in the management and surgical treatment of glaucoma, a leading cause of blindness in the world. Founded in 2000 by a serial ophthalmology entrepreneur, SOLX is financially-backed by MVM Life Science Partners, a leading global life science venture capital firm.